

# Recent progress in mucosal vaccine development: potential and limitations

Nils Lycke

**Abstract** | Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are much needed. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and great expectations for new mucosal vaccines lie ahead. Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines.

There is general agreement that effective mucosal vaccines — that is, oral, nasal, sublingual and genital tract vaccines — could dramatically contribute to the improvement of global health by stimulating protective immune responses not only against mucosal infections but also against HIV, *Mycobacterium tuberculosis* and many other infections<sup>1,2</sup>.

Mucosal vaccines are advantageous compared with systemic vaccines from a production and regulatory perspective<sup>3,4</sup>. For example, vaccines for oral use do not require extensive purification from bacterial by-products, as the gut is already heavily populated by bacteria, whereas the same vaccine formulation injected parenterally, for example, would have unacceptable endotoxin levels. In addition, mucosal vaccines are practical for mass vaccination and do not involve the risk of spreading blood-borne infections, as can occur with contaminated injection needles. The ease of administration, better compliance and the possibility that they can be delivered by personnel without medical training are also viewed as benefits of mucosal vaccine strategies<sup>5,6</sup>, especially for preventing the pandemic spread of infections, such as influenza virus infections<sup>7–10</sup>.

Both live attenuated and non-living mucosal vaccines are being developed to meet the need for better protection against pathogens that gain access to the body through mucosal membranes. Mucosal vaccination can trigger both humoral and cell-mediated immune protection not only at mucosal sites but also systemically<sup>1,11</sup>. Indeed, mucosal immunizations strongly induce long-term B and T cell memory<sup>12,13</sup>. Protection against pathogens can, thus, be effectively achieved by

directing memory and effector immune cells to the mucosal membranes through tissue-specific homing receptors. B and T cells acquire mucosal homing properties only in the draining lymph nodes from specialized dendritic cells (DCs) that migrate from the mucosal tissue to these lymph nodes<sup>14</sup> (BOX 1). Hence, vaccination via the intramuscular or subcutaneous routes poorly promotes immune protection at mucosal membranes. Following mucosal immunization, antigen-triggered B and T cells leave the draining lymph nodes, transit through the lymph, enter the blood circulation and then 'seed' the mucosal tissues<sup>11,15</sup>.

The size of the mucosal tissues provides a formidable challenge to inducing protective immunity at the natural portals of pathogen entry<sup>12</sup>. In general, the strongest immune response is usually induced at the site of vaccine exposure and in anatomically adjacent mucosal sites (for example, an immune response can be induced in both the rectal and genital tract in response to a rectal vaccine). Of note, intranasal immunization efficiently stimulates a protective immune response in the lungs and upper respiratory tract and at distant sites, such as the gastric and genital tract mucosa, but it is rather poor at stimulating intestinal immune responses.

Mucosal vaccine-induced immune responses are initiated in specific mucosa-associated lymphoid tissue (MALT) structures<sup>1,12,16</sup>, such as the Peyer's patches in the small intestine in response to oral immunization or the tonsils and adenoids in the nasal cavity in response to nasal or sublingual immunization (FIG. 1). In addition, the colon patches, the appendix, the abundant small isolated lymphoid follicles in the small intestine, large intestine and respiratory tract, and the mesenteric lymph

Center for Mucosal Immunobiology and Vaccines (MIVAC), Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden.  
e-mail: [nils.lycke@microbio.gu.se](mailto:nils.lycke@microbio.gu.se)  
doi:10.1038/nri3251

**Box 1 | Migration of vaccine-induced B and T cells to distinct mucosal tissues**

The localization of mucosal lymphocytes is determined by their expression of integrins and chemokine receptors, such as CC-chemokine receptor 9 (CCR9) and CCR10. These molecules are specific for adhesion molecules on endothelial cells and chemokines that are differentially expressed in the various mucosal tissues<sup>137</sup>. For example,  $\alpha 4\beta 7$  integrin is expressed by IgA<sup>+</sup> B cells and plasmablasts, as well as mucosal CD4<sup>+</sup> and CD8<sup>+</sup> T cells, that are activated in mesenteric lymph nodes or Peyer's patches. This integrin can specifically attach to mucosal addressin cell adhesion molecule 1 (MADCAM1), a tissue-specific adhesion molecule that is expressed on high endothelial venules in the gut intestinal mucosa<sup>138,139</sup>. CCR9-expressing lymphocytes are attracted to epithelium that produces CC-chemokine ligand 25 (CCL25), such as that of the small intestine.

Homing properties are imprinted on antigen-activated lymphocytes by mucosal dendritic cells (DCs) — such as CD103<sup>+</sup> DCs — that function at the inductive sites. Interestingly, this imprinting function of CD103<sup>+</sup> DCs depends on their ability to metabolize vitamin A and produce retinoic acid, which is involved in the acquisition of homing properties that are required for lymphocytes to enter the mucosa<sup>140–142</sup>. Perhaps the specific targeting of an antigen in a vaccine to CD103<sup>+</sup> DCs could result in effective stimulation of mucosal T cell responses, as suggested by recent work<sup>143</sup>.

Moreover, CCL28 (also known as MEC) is expressed in the gastrointestinal and genital tracts, where it selectively attracts IgA<sup>+</sup> B cells and plasmablasts that express the chemokine receptor CCR10. This explains why intranasal immunization stimulates IgA antibody production in the genital tract, as B cells acquire CCR10 expression in the nasopharynx-associated lymphoid tissue, allowing them to home to the genital tissue<sup>144</sup>.

nodes are all viewed as inductive sites. The immune effector sites, to which protective B and T cells home following priming in the MALT, are restricted to the lamina propria and intra-epithelial compartments of the mucosal membranes<sup>13,15,17</sup>.

Following mucosal vaccination, the mucosal barriers to infection are reinforced, mainly through the induction of antigen-specific secretory IgA (SIgA) antibody production, which prevents pathogens and toxins from adhering to or infecting the epithelial cells and breaching the mucosal barrier<sup>11</sup>. In addition, specific effector T cells are distributed to mucosal sites to reinforce their barrier functions<sup>13,18</sup> (BOX 2). Mucosal vaccination may also alter the growth conditions for pathogens and thereby reduce susceptibility to infection. For example, by changing the secretion of host factors involved in mucosal resistance to infection (such as antimicrobial peptides, chemokines and cytokines), the mucosal membrane can better resist attacks from intruding pathogens<sup>19,20</sup>.

Although the route of vaccination is important for a successful result, the selection of an appropriate formulation and adjuvant is also crucial for effective mucosal immunization using non-living vaccines. The reason for this is that tolerance is the natural immune response induced in response to a soluble antigen at mucosal sites. Mucosal tolerance prevents harmful inflammatory responses, for example to food antigens<sup>16,20</sup>, and has a role in the establishment of homeostasis between the microbiota and the host at mucosal membranes<sup>21</sup>. A particular problem with mucosal antigen exposure is, thus, the risk of inducing mucosal tolerance rather than protective immunity<sup>11,16</sup>. Adjuvants trigger innate immunity to support the induction of effector rather than regulatory T cell responses and, therefore, adjuvants are crucially needed to stimulate strong mucosal immune responses.

**Adjuvant**

An agent that enhances the immunogenicity of an antigen. Etymologically, the term adjuvant comes from the latin verb *adjuvare*, which means 'to help'.

**Mucosal tolerance**

Specific unresponsiveness to systemic challenges after a prior mucosal exposure to the antigen.

**Subcomponent vaccines**

Non-living vaccines that consist of whole cell walls or complete protein structures.

Here, I review some of the main strategies that have been used for successful mucosal vaccination and discuss the importance of the formulation, route of administration and adjuvant choice for achieving protective immunity at mucosal membranes. In addition, I comment on the recent progress in mucosal vaccine and adjuvant development and the novel strategies for finding correlates of protection through systems biology approaches.


**Strategies for mucosal vaccination**

Only a few commercially available mucosal vaccines currently exist. Although many mucosal vaccine candidates have been found to be effective in animal models, clinical trials have often failed. However, live attenuated mucosal vaccines against influenza virus, rotavirus and *Salmonella enterica* subsp. *enterica* serovar Typhi (the causative agent of typhoid fever) have been successfully launched. Moreover, two non-living whole-cell oral vaccines against *Vibrio cholerae* (marketed as Dukoral (Crucell) and Shanchol (Shantha Biotechnics)) provide proof-of-concept that non-living vaccines can also be effective via the mucosal route<sup>6,22</sup>. Unfortunately, the stability of live attenuated vaccines is still a problem, whereas non-living whole-cell or subcomponent vaccines are usually poorly immunogenic and require effective mucosal adjuvants. Therefore, many laboratories are focused on developing new and effective mucosal adjuvants (see below).

**Live attenuated vaccines.** Live attenuated vaccines are composed of live bacteria or viruses that are made much less virulent than the pathogenic parental bacterial or viral strains. The most important feature of live attenuated vaccines is that they provide a high level of antigen exposure and to some extent also have in-built adjuvanticity<sup>23</sup>. Live bacteria and viruses can also be engineered to carry recombinantly expressed antigens from other pathogens and, thus, can act as vaccine vectors. However, vaccine vectors that express recombinant antigens may be less effective than live attenuated vaccines owing to the presence of pre-existing vector-specific immunity that could lower vaccine efficacy, as has been reported with adenovirus vectors<sup>24</sup>.

Ideally, live attenuated vaccines establish a mild infection at the site of administration. They can also be engineered to have a limited capacity for replication and to deliver a sufficiently high antigen load at the site of immunization to be effective, while avoiding unwanted local inflammatory responses<sup>25</sup>. These attributes are important because prolonged antigen exposure and a large amount of antigen are usually required for the induction of mucosal immune responses, especially following oral vaccination<sup>26</sup>.

A major challenge for the development of live attenuated vaccines is the balance between sufficient attenuation and vaccine immunogenicity. For example, the effective live attenuated vaccines against rotavirus infection have been made less virulent (that is, less infectious) through serial passage of the virus in host cell cultures<sup>25,27</sup>. These vaccines result in only a



**Figure 1 | Mucosal immunization routes and compartmentalization of effector functions.** Within the mucosa-associated lymphoid tissue (MALT), subcompartments can be identified, such as the nasopharynx-associated lymphoid tissue (NALT), bronchus-associated lymphoid tissue (BALT), gut-associated lymphoid tissue (GALT) and genital tract-associated lymphoid tissue. Certain immunization routes are more effective at stimulating immunity within specific, most often closely located, subcompartments of the MALT. Intranasal vaccination is preferred for targeting the respiratory, gastric and genital tracts; oral vaccination is effective for immunity in the gut and for the induction of mammary gland antibodies (which are secreted in milk); rectal immunization is best for the induction of colon and rectal immunity and to some extent genital tract immunity; and intravaginal vaccination is the most effective for antibody and T cell immunity in the genital tract.

mild subclinical infection and are, thus, sufficiently attenuated, while still being highly immunogenic. By contrast, the live oral Ty21a typhoid vaccine is only moderately immunogenic, but it is safe because of extensive attenuation. However, the molecular basis for the attenuation of these vaccines is poorly understood<sup>25,28</sup>. The production of a new generation of live *S. Typhi* vaccines, designed to be administered in a single dose, was achieved by attenuation through selected gene deletion, giving rise to a safe and highly immunogenic vaccine<sup>25,29</sup>. Thus, precise gene deletions represent a more controlled strategy for attenuation than serial passage, and this approach is highly attractive for developing stable and safe live vaccines. A better understanding of the genetic basis for attenuation will be crucial for the next generation of live vaccines, and will allow for vaccines with increased safety and stability.

Several live attenuated mucosal vaccines are currently being developed. Most of the vaccines of this type that are being evaluated in clinical trials are oral vaccines, typified by vaccines against *Shigella* spp. (the causative agents of shigellosis) and *Salmonella* infections, but

some are intranasal and sublingual vaccines against *Bordetella pertussis* (the causative agent of whooping cough), influenza virus, rotavirus, norovirus and measles virus<sup>25,30–32</sup>.

**Non-living whole-cell or subcomponent vaccines.** Although attenuated vaccines are immunogenic and can deliver high levels of antigen to the mucosal target site, their development is a multistep process that often fails to generate safe and stable vaccines. Therefore, the development of non-living whole-cell or subcomponent mucosal vaccines is still much warranted. A large number of candidate vaccines are being developed, including inactivated influenza virus, norovirus and *Shigella* spp. vaccines<sup>10,32–34</sup>. Various delivery strategies are being adopted, with intranasal and oral administrations being the most used immunization routes in clinical trials. Particulate vaccine formulations (see below) are generally more effective at mucosal surfaces than soluble antigens, but it is generally thought that both types of vaccine require adjuvants that are more efficacious than those currently available to improve their immunogenicity.

**Existing mucosal vaccines.** The mucosal vaccines that are licensed and available<sup>25,27,35–37</sup> (TABLE 1) have been used to vaccinate populations in both developing countries and industrialized countries, and they have achieved considerable success in disease prevention<sup>3</sup>. For example, the recently developed rotavirus vaccines have proven effective in infants, although their efficacy is 30% lower in developing countries than it is in developed countries, probably owing to differences in nutritional status, gut microflora and/or pre-existing natural or maternal antibodies<sup>38,39</sup>. This highlights a crucial problem that has hampered the global success of mucosal vaccines, namely the poor outcome of these vaccines in developing countries, referred to as a tropical barrier<sup>3</sup>. Indeed, other oral vaccines — including vaccines against *V. cholerae* and prototypic vaccines against enterotoxigenic *Escherichia coli* (ETEC) — have been found to be less effective in developing countries than in developed countries<sup>3,25</sup>. The mechanisms involved in the tropical barrier are still incompletely understood, but chronic environmental enteropathy is a cardinal feature associated with this vaccine inefficacy. Chronic environmental enteropathy is marked by intestinal inflammation and blunting of the small intestinal villi, which leads to malabsorption of nutrients and a lack of vitamin A (and its derivative retinoic acid) and/or zinc. These deficiencies hamper the development of mucosal immune responses<sup>4,14,40</sup>; for example, a lack of retinoic acid directly impairs DC function in the gut mucosa<sup>41</sup>. Furthermore, persistent infections with helminths or other parasites, which are common in developing countries, may skew or suppress mucosal immune responses<sup>42</sup>. Therefore, the treatment of such infections could help to increase mucosal vaccine efficacy in developing countries. In addition, a more controlled strategy for pathogen attenuation through specific gene deletions is being investigated. Indeed, the use of precise and

**Tropical barrier**  
An inability to fully respond to mucosal vaccination, especially oral vaccination, in developing countries.

## Box 2 | Mucosal vaccine-induced protective local and systemic immune responses

**Secretory IgA**

IgA<sup>+</sup> B cells arise from naive B cells in mucosa-associated lymphoid tissue (MALT) following class-switching from IgM to IgA. This class-switching is induced by antigen stimulation and the presence of transforming growth factor- $\beta$  (TGF $\beta$ ) and to a lesser extent interleukin-10 (IL-10) and B cell-activating factor (BAFF). Both T cell-dependent and T cell-independent pathways lead to the production of IgA. The T cell-dependent pathway is crucial for vaccine responses, whereas the T cell-independent pathway has a role in mucosal homeostasis with the microbiota.

Clinical evidence indicates that secretory IgA has a neutralizing function on toxins and other soluble molecules and prevents bacterial adhesion to epithelial cells. Neutralizing IgA may also protect against intracellular viral infections in epithelial cells and function to dispose of viruses and potentially toxic substances through direct binding in the lamina propria of the mucosa.

**T<sub>H</sub>1 and T<sub>H</sub>2 cells**

Protection against many bacterial and viral infections relies on the effective stimulation of effector T helper 1 (T<sub>H</sub>1) cells, whereas T<sub>H</sub>2 cells have an indirect role by supporting antibody production. In models of infection with *Chlamydia trachomatis*, *Helicobacter pylori*, herpes simplex virus, influenza virus and *Mycobacterium tuberculosis*, a clear association between an improved T<sub>H</sub>1 cell-mediated immune response induced by mucosal vaccination and protection has been shown. However, direct evidence in humans for a strong correlation between T<sub>H</sub>1 cell-mediated responses and protection is still lacking.

**T<sub>H</sub>17 cells**

These effector CD4<sup>+</sup> T cells, defined by their production of IL-17, are found in the mucosal lamina propria and have been implicated in protection against several bacterial infections, including *H. pylori*, *Streptococcus pneumoniae*, *M. tuberculosis*, *Klebsiella* spp. and *Bacillus anthracis* infections<sup>145</sup>. Although T<sub>H</sub>17 cells are particularly frequent in the gastrointestinal mucosa, as a consequence of bacterial colonization, their ultimate function in gut homeostasis is still not well understood. However, it is known that responses influenced by IL-17 are crucial for maintaining the mucosal barrier, through the recruitment of neutrophils and the release of antimicrobial peptides and defensins<sup>19,122,146</sup>.

**Cytotoxic CD8<sup>+</sup> T cells**

CD8<sup>+</sup> T cells develop into cytotoxic T lymphocytes (CTLs) at mucosal membranes following vaccination, and CTLs have been studied in the context of immune protection against HIV-1, human papillomavirus, herpesviruses and *M. tuberculosis*. However, the protective capacity of cell-mediated immunity induced by mucosal vaccines has not yet been firmly established in human vaccine recipients<sup>13,147</sup>.

appropriate gene deletions to control the safety and stability of live attenuated vaccines and to improve their immunogenicity is another approach that might enhance vaccine efficacy in developing countries.

The only licensed non-living mucosal vaccine available for human use is the oral cholera vaccine. This vaccine, named Dukoral, was developed in the 1970s and early 1980s and consists of killed whole *V. cholerae* bacteria admixed with recombinant cholera toxin subunit B (CTB)<sup>22,43</sup>. It conveys protection even 2–3 years after vaccination, and the resulting protective immune response is dominated by antibacterial SIgA. The SIgA is mainly specific for *V. cholerae* lipopolysaccharide, but CTB-specific antibodies are also produced following vaccination<sup>44,45</sup>. These CTB-specific antibodies also convey short-term cross-protection against ETEC, owing to the similarity between CTB and the B subunit of the heat-labile toxin from ETEC<sup>1,46</sup>. These gut SIgA antibodies inhibit bacterial colonization and the binding of the toxins to intestinal epithelial cells<sup>22,46</sup>.

An important feature of the cholera vaccine is its ability to stimulate herd immunity<sup>47</sup>. This is a hallmark of mucosal vaccines, as pathogen-specific SIgA antibodies prevent infection and therefore reduce the virulence and spread of infection. Hence, even if the efficacy of a mucosal vaccine is lower than that of most parenteral vaccines, it might effectively prevent the spread of infection in a given population. Therefore, future research should be devoted to better understanding SIgA-dependent herd immunity and how it can be exploited for the prevention of mucosal infections<sup>48</sup>.

In sum, there are many strategies — such as the use of targeted gene deletions and the improvement of adjuvant functions — currently being used to refine the next generation of mucosal vaccines. These developments will result in mucosal vaccines that are more stable and more immunogenic, and that can better promote strong long-term memory responses and herd immunity.

**Mucosal vaccine delivery routes**

Mucosal vaccination was initially dominated by oral vaccines. The development of intranasal vaccines followed, and today we are exploring many different routes for the delivery of mucosal vaccines, including aerosol inhalation and intravaginal, rectal and sublingual routes (FIG. 1). Vaccine delivery via most of these routes works well in experimental animal models, but only the oral and intranasal routes have so far been used for licensed human vaccines<sup>49</sup>.

**Oral vaccination.** Oral vaccines represent the biggest challenge for mucosal vaccine development. This is not only because of the harsh gut environment, which degrades most antigenic epitopes that are delivered in soluble form, but also due to mucosal tolerance, which protects against unwanted immune responses to digested antigens. A plethora of studies have reported success in experimental animals with oral vaccine delivery, although results in ensuing clinical trials have mostly been disappointing<sup>25,49</sup>. Hence, it appears that more sophisticated formulations

**Herd immunity**

Protection against spread of infection in a population based on a critical mass of successfully vaccinated individuals.



Table 1 | Licensed mucosal vaccines

Vaccine	Trade name (developer)	Composition	Dosage and formulation	Mechanism of protection	Efficacy	Refs
Influenza type A and B viruses	FluMist (MedImmune)	Live viral reassortant with trivalent mix of H1, H3 and B strains of haemagglutinin and neuraminidase genes in an attenuated donor strain	Intranasal in young children, 2 doses	Haemagglutinin- and neuraminidase-specific mucosal IgA and systemic IgG responses; possibly a role for cell-mediated immunity; heterotypic protection effective in children	>85% in children, variable in adults	9,34, 37,81
H1N1 influenza virus (swine flu)	NASOVAC (Serum Institute of India)	Monovalent live attenuated vaccine	Intranasal spray, 1–2 doses	Haemagglutinin- and neuraminidase-specific mucosal IgA and serum IgG antibodies; possibly cell-mediated immunity	Unavailable	148
Rotavirus	RotaTeq (Merck); Rotarix (GlaxoSmithKline)	Monovalent, live attenuated human rotavirus and multivalent animal–human reassortant rotavirus	Oral, 3 doses	Mucosal IgA and systemic neutralizing IgG antibodies specific for homotypic or heterotypic VP4 and VP7 antigens	>70–90% against severe disease	27,38, 39,42
Poliovirus	Many	Trivalent, bivalent and monovalent vaccines	Oral, 3 doses	Mucosal IgA and systemic IgG neutralizing antibodies	>90% in most of the world	25,149, 150
Salmonella Typhi	Vivotif (Crucell); Ty21A	Live attenuated <i>S. Typhi</i> (Ty21A)	Oral, 3–4 doses of Ty21A	Mucosal IgA and systemic IgG antibody responses and CTL responses	Variable, but >50%	3,4,25,29, 35,48,151
<i>Vibrio cholerae</i>	Orochol (Crucell)	Live recombinant vaccine lacking CTA (CVD 103HgR)	Oral, single dose	Vibriocidal antibodies (possibly not the main effector mechanism but correlate well with protection)	Poor effect in a field trial	4,5,22,36, 43–47,114
Cholera	Dukoral (Crucell); Shanchol (Shantha Biotechnics)	Whole killed <i>Vibrio cholerae</i> O1 classical and El Tor biotypes with (Dukoral) or without (Shanchol) CTB	Oral, 2–3 doses	Gut antitoxin- and CTB-specific IgA and antibacterial and LPS-specific antibodies	Strong herd protection; >85% short term; >60% 3–5 years	4,5,22,36, 43–47,114

CTA, cholera toxin subunit A; CTB, cholera toxin subunit B; CTL, cytotoxic T lymphocyte; LPS, lipopolysaccharide.


using both cell-specific targeting approaches and immunomodulation will be required. Attempts to develop live attenuated oral vaccines are continuing, but stronger immunogenicity and better stability and safety profiles are required to launch new live mucosal vaccines, and this appears to be difficult to achieve<sup>3</sup>. Therefore, non-living vaccines containing strong mucosal adjuvants are much warranted. Although we know that particulate antigens are more immunogenic than soluble vaccine formulations at mucosal sites, we still lack a licensed oral vaccine based on, for example, biodegradable microparticles and nanoparticles adjuvanted by a mutated enterotoxin or Toll-like receptor (TLR) agonist<sup>50,51</sup> (see below). Notwithstanding these hurdles, it should be pointed out that effective oral vaccines do exist, with rotavirus and cholera vaccines as representative examples. However, at present we lack a good understanding of why these oral vaccines work when others do not. Hence, it has not been possible to mimic these successful vaccines by simply using the same formulations or protocols. It could be speculated that these oral vaccines can deliver sufficient antigen for sustained time periods to effectively prime the gut immune system, by gaining access to follicle-associated epithelium (FAE) and the Peyer's patches (discussed below).

**Intranasal vaccination.** Intranasal vaccination stimulates immune responses in the nasopharynx-associated lymphoid tissue (NALT) and is effective at inducing systemic and mucosal immunity in the gastric mucosa and the respiratory and genital tracts<sup>52,53</sup> (FIG. 2). For example, intranasal administration of a live attenuated influenza virus vaccine (FluMist; MedImmune) has proven effective at protecting against seasonal infection, and it even provides cross-protection against drifted influenza virus strains (which arise through the continuous process of genetic and antigenic change in influenza virus)<sup>9,54</sup>. In addition, recent attempts at stimulating protective immunity against gastrointestinal infections, such as *Shigella flexneri* infections, via the intranasal route have been successful<sup>25,32</sup>. In general, intranasal vaccination is an attractive approach, as much lower antigen and adjuvant doses are required compared with oral vaccination. Furthermore, vaccine delivery via aerosol spray and droplets is an attractive possibility owing to the development of new delivery devices<sup>55,55,56</sup>.

Moreover, intranasal immunization is effective at inducing antibody responses in the genital tract<sup>57</sup> (FIG. 2). This has obvious practical implications for the development of mucosal vaccines against sexually transmitted diseases. A promising strategy in HIV-1 vaccine development has been suggested by a study in

**Biodegradable microparticles and nanoparticles**

Particles that are 1–1000 nm in size and made from materials that self-disintegrate, such as poly(lactide-co-glycolide). Biodegradable microparticles and nanoparticles have been extensively used in different mucosal vaccine formulations and are gaining increased attention for their ability to serve as viable carriers for site-specific delivery of vaccines. They offer enhanced biocompatibility, superior vaccine encapsulation and convenient release profiles for mucosal vaccines.



**Figure 2 | Intranasal vaccination stimulates immune responses in the nasopharynx-associated lymphoid tissue.** The nasopharynx-associated lymphoid tissue (NALT) is composed of the lymphoid tissues in the Waldeyer’s ring, including the adenoids and the lingual and palatine tonsils. It is an attractive inductive site for stimulating immune responses against airborne and alimentary antigens. Antigens are taken up by the follicle-associated epithelium (FAE) overlaying the NALT, where dendritic cells (DCs) prime naive CD4<sup>+</sup> or CD8<sup>+</sup> T cells. Activated CD4<sup>+</sup> T cells differentiate into T helper 1 (T<sub>H</sub>1), T<sub>H</sub>2 and T<sub>H</sub>17 cells, regulatory T cells and, importantly, T follicular helper (T<sub>FH</sub>) cells. T<sub>FH</sub> cells help the development of long-lived plasma cells and memory B cells through the germinal centre reaction. Intranasally administered adjuvants enhance immune responses mainly by augmenting the innate immune response through the upregulation of co-stimulatory molecule, chemokine and cytokine expression. Such molecules include CD80, CD86, CD40, interferon- $\alpha$  (IFN $\alpha$ ), B cell-activating factor (BAFF) and a proliferating-inducing ligand (APRIL). DCs are the main targets of most adjuvants, but follicular dendritic cells (FDCs) may also be activated, as seen with the adjuvant CTA1-DD. Memory B and T cells migrate to draining lymph nodes and the non-organized effector tissues, such as the lungs and the genital tract. Crucial cytokines for germinal centre development in the NALT are shown. Nasal vaccines are formulated as sprays or droplets. CXCL13, CXC-chemokine ligand 13; ICAM1, intercellular adhesion molecule 1; IL, interleukin; TGF $\beta$ , transforming growth factor- $\beta$ ; VCAM1, vascular cell adhesion molecule 1.

which rhesus macaques were intranasally vaccinated with a virosome-coupled trimeric gp41 protein, which elicited strong protective IgA antibody responses in the genital tract and also prevented the transmission of infection<sup>58</sup>. Phase I clinical trials are now underway with intranasal delivery of this HIV-1 candidate vaccine<sup>59</sup>. Although intranasal immunization in females results in strong genital tract antibody responses, the stimulation of genital tract T cells appears to require local vaginal vaccination. Thus, combining intranasal priming and intravaginal boosting immunizations could be an effective strategy to achieve strong immune protection in the genital tract<sup>60,61</sup>. Indeed, the poor priming ability of the vaginal route, at least in the absence of an effective adjuvant, was highlighted in a recent clinical trial by the failure of an HIV-1 gp140 vaccine delivered vaginally to induce significant immune responses in healthy women<sup>62</sup>.

**Sublingual vaccination.** The sublingual route for vaccine administration is gaining interest<sup>63</sup>. Unexpectedly, vaccine delivery via this route stimulates broad and disseminated mucosal and systemic immune responses, similarly to the intranasal route<sup>64</sup>. Sublingual vaccination with soluble or particulate antigens (including live or killed bacteria and viruses) evokes strong mucosal IgA and systemic IgG antibody responses as well as

cytotoxic CD8<sup>+</sup> T cell responses<sup>65–67</sup>. Moreover, sublingual immunization with human papillomavirus (HPV) or *Chlamydia muridarum* antigens provides protection against genital infection by these pathogens<sup>65,66</sup>. In contrast to intranasal immunization, this route avoids the perturbation of central nervous system functions (which can result in Bell’s palsy) by adjuvants such as cholera toxin and *E. coli* heat-labile toxin (see below). This route also requires substantially lower amounts of antigen compared with oral immunization<sup>63</sup>.

Protection against lung infection appears to be stimulated by sublingual immunization, as seen in the case of influenza virus vaccination<sup>68</sup>. Furthermore, experimental sublingual immunization with *Helicobacter pylori* antigens or with ETEC or *V. cholerae* antigens effectively induces protective immunity in the stomach and intestine, respectively. This finding indicates that the tropical barrier may be circumvented by this route, as the antigen would not have to pass down the intestinal canal to prime B and T cells with gut-homing properties<sup>63,69</sup>. Clinical trials using sublingual vaccination are underway<sup>70</sup>.

**Mucosal vaccine formulations**

No vaccine is effective unless it is formulated in a way that promotes its immunogenicity. This means that it should preferably include components that enable the effective uptake of the antigens across the mucosal

**Follicle-associated epithelium (FAE).** The epithelium that overlies mucosal lymphoid tissues, such as the Peyer’s patches and isolated lymphoid follicles in the intestine. Lymphoid tissues induce the differentiation of normal intestinal epithelium into FAE, which is specialized in antigen capture and transport.

membrane. It has been found that antigens delivered in particles are better recognized by the innate immune system and, hence, are stronger inducers of mucosal immune responses than soluble antigens.

**Soluble formulations.** There are various soluble formulations for non-living mucosal vaccines. The access of vaccine antigens to the underlying tissues, where they activate immune cells, is impeded by a constantly renewing mucus layer that covers mucosal tissues. Thus, to increase the chances of effective antigen uptake, mucosal vaccines have been developed to include components — such as the mucoadhesives chitosan and starch — that improve adhesion to mucosal membranes<sup>71</sup>. The aim is to create close contact between the soluble vaccine antigens and the mucosal membrane. Use of these soluble formulations has been partly successful, although the choice of adjuvant rather than the mucoadhesive appears, in many cases, to be key for vaccine efficacy. Nevertheless, chitosan has been shown to have both mucoadhesive and adjuvant properties and in this way can fulfil two functions that enhance vaccine efficacy (TABLE 2). Notably, mucoadhesive formulations have been shown to effectively enhance intranasal and intravaginal immunizations, probably owing to prolonged antigen retention<sup>72,73</sup>.

**Particulate formulations.** Vaccines based on particulate formulations have generally been more effective than soluble antigens at stimulating protective immunity<sup>50,51,74–76</sup>. Examples of such formulations include virus-like particles (VLPs), bacterial ghosts, biodegradable microparticles and nanoparticles (such as PLG (poly(lactide-co-glycolide))-containing microparticles and liposomes) and immunostimulating complexes. Particulate vaccines can also establish a close contact with the mucosal epithelium through the inclusion of anchoring devices that have adhesive properties (such as lectins and specific antibodies) or through the inclusion of immunomodulating molecules (such as TLR ligands and CTB) that bind to distinct receptors<sup>50,51</sup>. Thus, the particles can be developed to have both bioadhesive and immunomodulating properties.

Targeting a particle to the mucosal membrane also facilitates antigen uptake across the epithelial barrier through the specialized FAE, which overlies the MALT<sup>77</sup>. This allows the particle to be targeted to antigen-presenting cells (APCs) and to directly modulate the release of chemokines and cytokines to enhance T cell priming through increased co-stimulation. A particular type of FAE that is composed of microfold (M) cells and found over the NALT and the Peyer's patches has special properties that enable the engulfment and transcellular transport of antigens to the subepithelial dome, where the antigens can stimulate specific CD4<sup>+</sup> T cells in the interfollicular region<sup>78</sup>. The targeting of mucosal vaccines to M cells has been successfully explored using TLR agonists, specific lectins (such as *Ulex europaeus* agglutinin 1) and antibodies specific for M cell surface markers (such as glycoprotein 2)<sup>79</sup>.

Although work with mucosal vaccine formulations has been ongoing for more than two decades, we still lack licensed vaccines based on these approaches. Thus, the future challenge is to develop novel mucosal vaccine formulations that meet the demand for safe and effective delivery of vaccine antigens. Perhaps nanotechnology-based vaccines will prove to be the most effective delivery vehicles for non-living subcomponent mucosal vaccines, as their size, contents and cell-targeting properties can be engineered. However, we are only beginning to understand the optimal chemical composition of nanoparticles for the effective stimulation of mucosal immune responses<sup>50,51</sup>.

### Mucosal vaccine adjuvants

The selection of adjuvants for a mucosal vaccine is as crucial as the selection of the antigen (or combination of antigens). Recent data from humans and experimental models have shown that the choice of adjuvant can dramatically affect not only the immediate immune response but also the long-term protective effect of a vaccine<sup>23,80</sup>. Also, the quality of the immune response — especially the development of high-affinity B cell clones, long-lived memory B cells and plasma cells — can be influenced by the choice of adjuvant<sup>80</sup>. Furthermore, by using whole-genome phage-display libraries to test antibody recognition, recent studies with influenza vaccines have demonstrated that adjuvants may dramatically augment epitope spreading following vaccination, which could lead to the production of higher avidity antibodies with improved neutralizing properties<sup>81</sup>.

From a mechanistic point of view, mucosal adjuvants modulate innate immune responses in the same way as adjuvants in injectable vaccines<sup>26,82,83</sup> (TABLE 2). Thus, TLR agonists constitute a major category of mucosal adjuvants<sup>84</sup>. These adjuvants are based on pathogen-associated molecular patterns (PAMPs), which are often formulated in oil-in-water emulsions. For example, the commercial adjuvant IC31 and other CpG oligodeoxynucleotide (ODN)-containing formulations, which act through TLR9, have been used successfully in experimental vaccine models and in clinical trials<sup>85</sup>. Monophosphoryl lipid A, which signals through TLR4, and the TLR5 ligand flagellin have also been used as adjuvants in mucosal immunizations and have shown intermediate potency<sup>86</sup>. Cationic liposomes (composed of the synthetic amphiphile dimethyldioctadecylammonium (DDA), for example) and the saponin derivative QS21 have been found to be effective for mucosal immunization, although the mechanism for their action is poorly understood<sup>87–89</sup>. The combination of a particulate vaccine formulation with an adjuvant has been found to be superior in many cases; for example, coating a CpG ODN onto microparticles enhances the immunostimulatory capacity of this TLR9 agonist in mucosal vaccination<sup>90</sup>.

The second category of mucosal adjuvants includes the most effective immunomodulators known today: the bacterial enterotoxins cholera toxin and *E. coli* heat-labile toxin, which have considerable sequence

#### Virus-like particles

Virus envelopes without nucleic acid that are used for the delivery of vaccine antigens.

#### Bacterial ghosts

Empty cell envelopes of Gram-negative bacteria devoid of cytoplasmic content and chromosomal and plasmid DNA that are used for the delivery of vaccine antigens.

#### Immunostimulating complexes

(ISCOMs). Spherical open cage-like structures (typically 40 nm in diameter) that spontaneously form from a mixture of cholesterol, phospholipids and *Quillaja* saponins. ISCOMs are used as vaccine adjuvants to induce an enhanced immune response and protection.

#### Epitope spreading

The process by which an antibody response to one epitope of an antigen leads to the production of antibodies specific for other epitopes of the same antigen, or for epitopes of entirely unrelated antigens. This results from the internalization of the whole antigen and the subsequent display of a range of peptides derived from that antigen, leading to the generation of T cells with different epitope specificities. Simultaneous processing of two unrelated antigens by an antigen-presenting cell can lead to the production of antibodies directed against both antigens.

Table 2 | Mucosal adjuvants

Type of adjuvant or delivery system	Composition	Target	Formulation	Immuno-enhancement	Mucosal IgA	Clinical testing?	Licensed vaccine?	Refs
TLR ligands	MDP	TLR2	Soluble or conjugated	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells	+	Yes	No	152
	MPL	TLR4	Emulsion or liposomes	T <sub>H</sub> 1 cells, CTLs	+	Yes	No	23,83
	Flagellin	TLR5	Soluble or conjugated	T <sub>H</sub> 1 cells, CTLs	++	Yes	No	86
	CpG	TLR9	Soluble, with or without PLG or CTB	T <sub>H</sub> 1 cells, CTLs	–	Yes	No	23,83,85
Enterotoxins	CT	GM1	Soluble or conjugated	T <sub>H</sub> 2 cells, T <sub>H</sub> 17 cells, CTLs	+++++	Yes	No	2,6,26,43, 82,91,93,94, 96,97,153
	CTB	GM1	Soluble or conjugated	ND	+	Yes	Yes	43
	CTA1-DD	Immuno-globulin heavy chain, complement	Soluble, conjugated to nanoparticles or incorporated in ISCOMs	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, T <sub>H</sub> 17 cells, CTLs	+++++	No	No	26,60,74, 107–111, 130,147, 154
	LT	GM1 and other gangliosides	Soluble or conjugated	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, T <sub>H</sub> 17 cells, CTLs	+++++	Yes	No	91–93, 95–98,104
	Mutant LT and CT	GM1 and other gangliosides	Soluble or conjugated	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, T <sub>H</sub> 17 cells, CTLs	++++	Yes	No	91,92,100, 102,103, 105
Mucoadhesives	Chitosan	Tight junctions	Soluble or conjugated	T <sub>H</sub> 2 cells	++	Yes	No	71,72
	Lectins (such as UEA1)	M cells	Conjugated	ND	+	No	No	6
Particles	PLG	ND	Microspheres	T <sub>H</sub> 1 cells, CTLs	+	Yes	No	50,51
	Virus envelopes	ND	VLPs	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, CTLs	++	Yes	Yes	58,76
	Bacterial cell membranes	ND	BCVs	T <sub>H</sub> 1 cells, CTLs	+	Yes	No	155
	Phospholipids	ND	Liposomes	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells	+	Yes	No	51,75
	<i>Quillaja</i> saponins	DCs	ISCOMs or ISCOMATRIX	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, CTLs	++	Yes	No	26,74
Saponins	<i>Quillaja</i> saponins fraction		QS21 soluble	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, CTLs	+	Yes	No	87
Oil-in-water and water-in-oil emulsions	Cationic DDA or liposomes	DC uptake	Liposomes	T <sub>H</sub> 1 cells, CTLs	++	Yes	No	88
	Squalene	ND	MF59	T <sub>H</sub> 1 cells	–	No	No	80
	Montanide ISA-51 or Montanide ISA-720VG	ND	Montanide	T <sub>H</sub> 2 cells	ND	Yes	No	65
	α-galactosylceramide	CD1d	Soluble	Vα14 <sup>+</sup> iNKT cells	++	No	No	84
Cytokines	IL-1	IL-1R	Soluble or plasmid DNA	T <sub>H</sub> 1 cells, T <sub>H</sub> 2 cells, CTLs	+++	No	No	156,157
	IL-12	IL-12R	Soluble or plasmid DNA	T <sub>H</sub> 1 cells, CTLs	+	No	No	157

BCV, bacterial ghosts vector; CT, cholera toxin; CTA1-DD, cholera toxin subunit A1–*Staphylococcus aureus* protein A D-fragment dimer; CTB, cholera toxin subunit B; CTL, cytotoxic T lymphocyte; DC, dendritic cell; DDA, dimethyldioctadecylammonium; IL, interleukin; iNKT, invariant natural killer T; ISCOM, immunostimulating complex; LT, *E. coli* heat-labile toxin; M cell; microfold cell; MDP, muramyl dipeptide; MPL, monophosphoryl lipid A; ND, not determined; PLG, poly(lactide-co-glycolide); TLR, Toll-like receptor; T<sub>H</sub>, T helper; UEA1, *Ulex europaeus* agglutinin 1; VLP, virus-like particle.



**Follicular dendritic cells (FDCs).** Stromal cells that are crucial for the development of germinal centres in B cell follicles. The interaction between FDCs and B cells is thought to be essential for isotype switching and somatic hypermutation.

**Somatic hypermutation**  
The process by which point mutations occur in the heavy- or light-chain variable region gene segments, resulting in a change in the expressed protein, which may alter the affinity or specificity of the antibody for an antigen.

similarity<sup>91,92</sup>. These enterotoxins are AB<sub>5</sub> complexes, in which the A subunit is comprised of an ADP-ribosylating A1 portion and an A2 chain that interacts with the pentamer of B subunits<sup>1,93</sup>. Mucosal immune responses using these holotoxin adjuvants are probably dependent on DCs<sup>94</sup>; however, current evidence suggests that they do not activate the innate immune system through TLRs or NOD-like receptors (NLRs)<sup>26</sup>. Instead, they bind via their B subunits to gangliosides (preferentially GM1) that are present on the cell membrane of most nucleated cells<sup>95</sup>. Following binding, the A1 portion mediates the ADP-ribosylation of the membrane-bound heterotrimeric guanine nucleotide-binding protein subunit Gsa, resulting in increased cytoplasmic levels of cyclic AMP<sup>96</sup>. The binding of these toxins to gangliosides facilitates their uptake across mucosal membranes and, perhaps, by the FAE<sup>97</sup>. However, gangliosides are ubiquitously expressed, and therefore these adjuvants can be associated with unwanted side effects. For example, intranasal administration of a mucosal VLP-based influenza vaccine containing *E. coli* heat-labile toxin as an adjuvant has resulted in the development of facial paralysis (Bell's palsy) in a few individuals, owing to the presence of gangliosides on nerve cells<sup>98–100</sup>. Furthermore, oral vaccination with cholera toxin or heat-labile toxin as the adjuvant has resulted in overt diarrhoea in some vaccine recipients<sup>101</sup>.

**Mutant enterotoxins are safer adjuvants.** Enterotoxins can be engineered into less toxic and safer mucosal adjuvants through site-directed mutations of the enzymatically active A1–A2 subunit<sup>102</sup>. In the case of *E. coli* heat-labile toxin, this has resulted in the generation of a single-mutant toxin (LTR192G) and a double-mutant toxin (LTR192G/L211A; known as dmLT), both of which appear to be effective for enhancing mucosal immune responses<sup>91,103</sup>. dmLT in particular is trypsin

resistant and, hence, is stable after oral administration, and because it exerts no enterotoxicity it holds promise as an oral vaccine adjuvant. dmLT is currently being tested experimentally in various models and will soon be assessed in clinical trials. Promising results from these studies could convey optimism for future use of mutated holotoxins in mucosal vaccines. This would pave the way for a renewed confidence from regulatory authorities in mucosal adjuvants based on cholera toxin and *E. coli* heat-labile toxin.

LTK63 is another genetically detoxified *E. coli* heat-labile toxin mutant that has been developed and has shown efficacy in humans. Although this mutant completely lacks enzymatic activity<sup>102,104</sup>, it was associated with the development of Bell's palsy in a few vaccine recipients in two recent intranasal vaccine clinical trials, thereby cautioning against the use of GM1-binding adjuvants in intranasal vaccines<sup>105</sup>. However, for oral or sublingual vaccination the neurotoxicity problem may not exist.


Mutants of cholera toxin that retain strong adjuvant activity have also been generated<sup>98,102,106</sup>. The mutations have mostly affected the enzymatically active cleft of cholera toxin subunit A (CTA), similarly to those used for *E. coli* heat-labile toxin, rendering the molecule enzymatically inactive. As an example, a double mutant of cholera toxin (CTA112/KDEV) was found to be safe and did not accumulate in the central nervous system, and retained good adjuvant function when administered intranasally<sup>106</sup>. It is presently not known whether the cholera toxin and heat-labile toxin mutants have similar adjuvant activities. However, it is likely that there would be minimal, if any, significant differences between the two families of mutant holotoxins with regard to adjuvant impact.

**Taking toxin adjuvants one step further.** To circumvent the problem with toxicity, we have developed a non-toxic derivative of cholera toxin, termed CTA1-DD<sup>107</sup>, which has been shown to be a highly effective adjuvant in mice, guinea pigs and non-human primates following admixing with numerous vaccine candidates<sup>108</sup>. CTA1-DD is a fusion protein of CTA1, which hosts the full enzymatic activity of the toxin, and a dimer of the D-fragment from *Staphylococcus aureus* protein A. Unlike cholera toxin and *E. coli* heat-labile toxin, CTA1-DD cannot bind to the ganglioside GM1, as it lacks the B subunit, and it has been shown to be non-toxic and safe in experimental animal models, including non-human primates<sup>109,110</sup>. Furthermore, it does not bind to nervous tissues and no side effects were observed following intranasal administration<sup>109</sup>. CTA1-DD has adjuvant effects comparable to those of cholera toxin and heat-labile toxin, and it enhances a wide range of immune responses following intranasal immunizations, including antibody, CD4<sup>+</sup> T cell and cytotoxic CD8<sup>+</sup> T cell responses<sup>26</sup> (BOX 3). Candidate vaccines containing CTA1-DD have been shown to enhance immunity to HIV-1, *Chlamydia trachomatis*, *H. pylori*, *M. tuberculosis*, rotavirus and influenza A virus<sup>26,110</sup>. By contrast, intranasal administration of an enzymatically inactive mutant of CTA1-DD (CTA1R7K-DD) with an

### Box 3 | Mechanisms of immune activation by the adjuvant CTA1-DD

The dimer of D-fragments from *Staphylococcus aureus* protein A that is linked to the enzymatically active A1 portion of cholera toxin (CTA1) in the CTA1-DD fusion protein activates the complement system<sup>148</sup>, primarily through the alternative pathway. The binding of CTA1-DD to the complement receptor CD21 on follicular dendritic cells (FDCs) results in strong stimulation of germinal centre formation and the development of long-lived plasma and memory B cells<sup>148</sup>. These germinal centre reactions were shown to be associated with enhanced somatic hypermutation and affinity maturation, resulting in the production of antibodies with higher affinities than those induced by adjuvants such as alum and monophosphoryl lipid A (MPL). This partly explains why CTA1-DD is especially effective at stimulating the production of neutralizing antibodies<sup>149</sup>. Although alum and MPL induce immediate serum antibody titres comparable with those induced by CTA1-DD, the half-life of specific serum IgG antibodies is dramatically prolonged with CTA1-DD<sup>108</sup>, supporting the notion that the choice of adjuvant could greatly influence both the quality and longevity of the vaccine response.

CTA1-DD was originally developed to target the B cell receptor, but its adjuvant effect also depends on DCs and can enhance the priming of CD4<sup>+</sup> T cells in a complement-independent manner<sup>148</sup>. Thus, the immunomodulating activity of CTA1-DD is most likely to be multifunctional and to have direct effects on both FDCs and DCs; for example, CTA1-DD greatly promotes the antigen-presenting functions of DCs. The extent to which B cells are directly affected by CTA1-DD is presently unclear, but T cell-independent antibody responses are not augmented by this adjuvant<sup>148</sup>.



**Figure 3 | Induction of gut IgA responses by mucosal vaccines.** In the gut, antigens are taken up by specialized microfold (M) cells overlaying the Peyer's patches. Subepithelial dome (SED)-resident dendritic cells (DCs) then take up and process these antigens, and naive CD4<sup>+</sup> T cells are primed in the interfollicular space. T follicular helper (T<sub>FH</sub>) cells expressing B cell lymphoma 6 and CXCR5 (not shown) interact with cognate B cells at the B cell follicular border. Next, T<sub>FH</sub> cells colocalize with B cells in the B cell follicle in close proximity to a follicular dendritic cell (FDC) network, and this allows the formation of a germinal centre. In the germinal centre, the antigen-specific B cells undergo class-switching to IgA and somatic hypermutation to generate higher affinity antibodies. The resulting IgA<sup>+</sup> long-lived plasma cells and memory B cells generated within the germinal centre leave the Peyer's patch through the efferent lymph and migrate to the mesenteric lymph nodes and then to the blood, from where plasma cells home to bone marrow and to effector sites in the lamina propria of the small and large intestine. The gut IgA response to oral vaccines is highly synchronized and strongly oligoclonal. Specific IgA<sup>+</sup> B cells and plasma cells in both the gut-associated lymphoid tissue and non-organized lamina propria are clonally related, suggesting that multiple Peyer's patches are involved in the build-up of protective immunity. This can only occur if already existing germinal centres in multiple Peyer's patches are involved in the process of expanding and selecting high-affinity antigen-specific IgA<sup>+</sup> B cells. In particular, the distribution of clonally related B cells to multiple Peyer's patches explains why repeated oral immunizations are needed to successfully drive high-affinity IgA responses in the gut lamina propria.

incorporated collagen peptide induced tolerance via interleukin-10 (IL-10)-producing regulatory T cells and protected against collagen-induced arthritis in mice<sup>111</sup>. This suggests that the ADP-ribosylating activity of CTA1 has a central role in determining whether immunity or tolerance is induced following mucosal immunization<sup>112</sup>. The use of the mutant CTA1R7K-DD for the treatment of autoimmune diseases is now being explored in our laboratory in animal models of rheumatoid arthritis, multiple sclerosis and type 1 diabetes.

#### Vaccine-induced long-term memory

**B cell memory.** Field trials of mucosal vaccines have shown that overall protection against infection can last for several years, even though intestinal IgA responses vanish after 6–9 months<sup>12,22,43</sup>. The longer duration of protection is thought to reflect the ability of IgA<sup>+</sup> memory B cells to elicit a rapid recall response to a

renewed exposure to the pathogen and thereby to improve the capacity for preventing infection<sup>12,113</sup>. These and other observations have demonstrated that mucosal vaccination can induce both memory IgA<sup>+</sup> and memory IgG<sup>+</sup> B cells, not only after oral immunization but also after intranasal and intravaginal vaccinations<sup>31,44,114–117</sup>.

The development of memory IgA<sup>+</sup> B cells following mucosal immunization has been studied in detail in mice<sup>12,26,108</sup>. The constitutive presence of germinal centres in Peyer's patches implies that these are important sites for generating long-lived plasma cells and memory B cells, although oral immunizations have not been shown to influence the overall number of germinal centres in the gut-associated lymphoid tissue (GALT)<sup>12</sup>. Cholera toxin-specific IgA<sup>+</sup> plasma cells were found in the gut lamina propria for up to 6 months following oral immunization with this toxin<sup>118,119</sup>. Although at

#### Germinal centres

The structures that are formed by the expansion of populations of antigen-activated B cell blasts that have migrated into the follicles of lymph nodes. The B cells in these structures proliferate and their immunoglobulin genes undergo somatic hypermutation, before the cells leave as plasma cells or memory B cells.

later time points toxin-specific IgA<sup>+</sup> plasma cells had disappeared, memory B cells remained in the GALT and could be triggered by a single re-exposure to oral cholera toxin, resulting in a vigorous IgA<sup>+</sup> plasma cell response in the lamina propria within 3 days<sup>18</sup>. Recently, we found evidence for extensive clonal relationships between antigen-specific secondary IgA<sup>+</sup> B cells in multiple Peyer's patches, suggesting that B cells can migrate from one Peyer's patch to another<sup>120</sup>. Therefore, it appears that, following an oral priming immunization, activated IgA<sup>+</sup> B cells can enter already existing germinal centres in multiple Peyer's patches, where they can continue proliferating and undergo affinity maturation (FIG. 3). By using already established germinal centres in multiple Peyer's patches, the IgA response can be synchronized, leading to the selection of only high-affinity B cell clones, provided that the antigen is present in the germinal centre. This explains why IgA<sup>+</sup> plasma cells in the lamina propria and memory B cells in the GALT are clonally related and oligoclonal. Accordingly, and contrary to the trend in parenteral vaccination, mucosal vaccine strategies need to consider repeated immunizations — for example, using live vectors, slow-release systems or repeated administrations — to ensure sustained antigen stimulation and to thereby drive high-quality IgA<sup>+</sup> B cell responses in the GALT.

**T cell memory.** Memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells are also generated by mucosal vaccination. Indeed, most T cells in the lamina propria are effector memory T cells<sup>121</sup>, and only low numbers of naive T cells are found there<sup>13</sup>. Although the function of these memory T cells in mucosal tissues is not fully understood, all the major effector and regulatory CD4<sup>+</sup> T cell subsets, as well as CD8<sup>+</sup> T cells, are present. In particular, T helper 17 (T<sub>H</sub>17) cells are frequent in the gut lamina propria, reflecting colonization by certain bacterial strains<sup>122,123</sup>. However, the exact protective functions of mucosal vaccine-induced memory T<sub>H</sub>1 and T<sub>H</sub>17 cells still await better definition (BOX 2). Indeed, both protective effector functions and immunosuppressive functions of T<sub>H</sub>17 cells in the intestine have recently been documented<sup>124</sup>. Resistance against *H. pylori* or *C. trachomatis* infection relies on the presence of memory CD4<sup>+</sup> T cells in the gastric and genital tracts, respectively, but the mechanisms of protection are much debated<sup>125,126</sup>. It appears, however, that tissue-resident memory T cell responses at mucosal sites can be activated in both an antigen-dependent and an antigen-independent manner, and in both cases this may limit pathogen replication<sup>127</sup>. A better understanding of the triggering factors and the function of these memory T cells for protection against pathogens is needed to allow for a more rational design of mucosal vaccines.

### Hurdles in mucosal vaccine development

A major goal in mucosal vaccine research is the development of efficiently attenuated live vaccines with improved stability and safety. Directed gene mutagenesis is likely to successfully generate more stable vaccine

vectors than random mutagenesis, which has been used previously. Good examples are the recent genetic engineering of the single-dose *S. Typhi* vaccines and the well-tolerated live *S. flexneri* 2a attenuated oral vaccine CVD1208 (REF. 31). Indeed, CVD1208 was shown to be as effective as the more reactogenic and less mutated CVD1204 vaccine at stimulating lipopolysaccharide-specific memory B cells, indicating that safety may not have to be compromised to achieve an efficacious mucosal vaccine.

Furthermore, effective targeting of particulate vaccine formulations combined with strong immunomodulation should improve the efficacy of non-living subcomponent mucosal vaccines. New strategies to target M cells using lectins and antibodies, as well as further exploration of the use of ligands for TLRs and complement receptors, will undoubtedly be given special attention. In addition, the development of more effective mucosal adjuvants is of key importance. Prototype vaccines have successfully targeted DCs by using antibodies specific for cell-surface receptors such as DEC205 (also known as LY75) and DC-SIGN, or by using the natural ligands of these receptors, such as mannan and mannoseylated liposomes<sup>128</sup>. Whether these targeting components will be effective in mucosal vaccines awaits full investigation. Moreover, a promising DC-specific target that was recently identified is C-type lectin domain family 9 member A (CLEC9A), activation of which stimulates antibody production<sup>129</sup>. Targeting derivatives of mutant holotoxins specifically to DCs could be an attractive way forward. For example, we are currently testing the effect of targeting CTA1 to DC-specific cell-surface receptors. Targeting adjuvants to cells expressing Fc receptors for IgG (FcγRs) could be an alternative strategy. Interestingly, intranasally administered CTA1-DD-IgG immune complexes were shown to activate mast cells and to enhance antibody production via FcγRIIIA<sup>130</sup>, highlighting the role of mast cells in augmenting mucosal immune responses.

We currently have only imprecise correlates of protection for most mucosal vaccines<sup>113</sup>. For example, toxin-specific salivary IgA antibody titres and serum vibriocidal antibodies are considered markers of protection against *V. cholerae*, although we do not know why serum vibriocidal antibodies can protect against a strictly intestinal mucosal infection<sup>125</sup>. A systems biology approach could help to identify biological markers for mucosal vaccine efficacy. Systems biology offers a new strategy for vaccine design that is based on understanding the molecular network that is activated by vaccination. Using functional genomics, specific molecular signatures of individual vaccines can be identified and used as predictors of vaccine efficacy<sup>131–135</sup>. In addition to complementing the conventional approaches to vaccine assessments, this approach investigates more general correlates of protection (beyond antigen-specific responses), including additional protective measures in the target tissues. To this end, complex tissue-specific interplay between epithelial cells, effector lymphocytes, inflammatory cells and nerve cells may be revealed, and such interactions could represent key

#### Affinity maturation

The mutation of antibody variable region genes followed by selection for higher affinity variants in the germinal centre leads to an increase in average antibody affinity as an immune response progresses.



protective measures that are involved, for example, in antitoxin immune responses in the intestine<sup>46,49</sup>. With this information, vaccine developers also hope to identify the very early immune events that occur after vaccination, in particular those crucial for memory development. Ultimately, this information will help our understanding of the mechanisms that underlie successful mucosal vaccination. By incorporating genomics, transcriptomics, proteomics, metabolomics

and mathematical modelling with studies of immune protection in humans and in experimental animal models, we could gain a better understanding of the efficiency of mucosal vaccination<sup>136</sup>. Finally, a continuous exchange of information between preclinical research and clinical vaccine development is much needed to secure improved formulations, adjuvants and delivery protocols for the next generation of effective mucosal vaccines.

1. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. *Nature Med.* **11**, S45–S53 (2005). **An excellent overview of the field with a special focus on oral vaccines.**
2. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. *Nature Rev. Immunol.* **6**, 148–158 (2006).
3. Levine, M. M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. *BMC Biol.* **8**, 129 (2010).
4. Walker, R. I. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. *Vaccine* **23**, 3369–3385 (2005).
5. Levine, M. M. & Dougan, G. Optimism over vaccines administered via mucosal surfaces. *Lancet* **351**, 1375–1376 (1998).
6. Yuki, Y. & Kiyono, H. Mucosal vaccines: novel advances in technology and delivery. *Expert Rev. Vaccines* **8**, 1083–1097 (2009).
7. Amorij, J. P., Hinrichs, W., Frijlink, H. W., Wilschut, J. C. & Huckriede, A. Needle-free influenza vaccination. *Lancet Infect. Dis.* **10**, 699–711 (2010).
8. Burt, D. *et al.* Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. *Expert Rev. Vaccines* **10**, 365–375 (2011).
9. Carter, N. J. & Curran, M. P. Live attenuated influenza vaccine (FluMist; Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. *Drugs* **71**, 1591–1622 (2011). **An updated review of the current status of the FluMist vaccine.**
10. Langley, J. M. *et al.* A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. *Vaccine* **29**, 1921–1928 (2011).
11. Brandtzaeg, P. Function of mucosa-associated lymphoid tissue in antibody formation. *Immunol. Invest.* **39**, 303–355 (2010). **An excellent overview of the mucosal immune system and its regulatory mechanisms.**
12. Brandtzaeg, P. Induction of secretory immunity and memory at mucosal surfaces. *Vaccine* **25**, 5467–5484 (2007).
13. Sheridan, B. S. & Lefrancois, L. Regional and mucosal memory T cells. *Nature Immunol.* **12**, 485–491 (2011).
14. Mora, J. R. & von Andrian, U. H. Role of retinoic acid in the imprinting of gut-homing IgA-secreting cells. *Semin. Immunol.* **21**, 28–35 (2009). **This review details the role of retinoic acid in the gut-homing ability of IgA<sup>+</sup> B cells.**
15. Kiyono, H. & Fukuyama, S. NALT versus Peyer's-patch-mediated mucosal immunity. *Nature Rev. Immunol.* **4**, 699–710 (2004).
16. Mowat, A. M., Millington, O. R. & Chirido, F. G. Anatomical and cellular basis of immunity and tolerance in the intestine. *J. Pediatr. Gastroenterol. Nutr.* **39**, S723–S724 (2004).
17. Brandtzaeg, P. Update on mucosal immunoglobulin A in gastrointestinal disease. *Curr. Opin. Gastroenterol.* **26**, 554–563 (2010).
18. Bevan, M. J. Memory T cells as an occupying force. *Eur. J. Immunol.* **41**, 1192–1195 (2011).
19. Blaschitz, C. & Raffatellu, M. Th17 cytokines and the gut mucosal barrier. *J. Clin. Immunol.* **30**, 196–203 (2010).
20. Feng, T. & Elson, C. O. Adaptive immunity in the host–microbiota dialog. *Mucosal Immunol.* **4**, 15–21 (2011). **This paper highlights the various elements in the interaction between the microbiota and host T cells in gut homeostasis.**
21. Slack, E. *et al.* Innate and adaptive immunity cooperate flexibly to maintain host–microbiota mutualism. *Science* **325**, 617–620 (2009). **An elegant study on the mutualism between the microbiota and the host with special reference to the role of TLR signalling.**
22. Czerkinsky, C. & Holmgren, J. Enteric vaccines for the developing world: a challenge for mucosal immunology. *Mucosal Immunol.* **2**, 284–287 (2009).
23. Manicassamy, S. & Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. *Semin. Immunol.* **21**, 185–193 (2009).
24. Tucker, S. N., Tingley, D. W. & Scallan, C. D. Oral adenoviral-based vaccines: historical perspective and future opportunity. *Expert Rev. Vaccines* **7**, 25–31 (2008).
25. Pasetti, M. F., Simon, J. K., Szein, M. B. & Levine, M. M. Immunology of gut mucosal vaccines. *Immunol. Rev.* **239**, 125–148 (2011). **An outstanding review of the field of oral vaccines.**
26. Lycke, N. in *Vaccine adjuvants and delivery systems* (ed. Singh, M.) 53–79 (John Wiley & Sons, 2007).
27. Greenberg, H. B. & Estes, M. K. Rotaviruses: from pathogenesis to vaccination. *Gastroenterology* **136**, 1939–1951 (2009). **A very comprehensive report on the background and efforts to develop rotavirus vaccines.**
28. Ruiz-Palacios, G. M. *et al.* Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *N. Engl. J. Med.* **354**, 11–22 (2006).
29. Kirkpatrick, B. D. *et al.* Evaluation of *Salmonella enterica* serovar Typhi (Ty2 aroC-ssaV) M012H09, with a defined mutation in the *Salmonella* pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. *Vaccine* **24**, 116–123 (2006).
30. Li, R., Lim, A. & Alonso, S. Attenuated *Bordetella pertussis* BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route. *Bioeng. Bugs* **2**, 315–319 (2011).
31. Simon, J. K. *et al.* Antigen-specific IgA B memory cell responses to *Shigella* antigens elicited in volunteers immunized with live attenuated *Shigella flexneri* 2a oral vaccine candidates. *Clin. Immunol.* **139**, 185–192 (2011).
32. Tribble, D. *et al.* Safety and immunogenicity of a *Shigella flexneri* 2a InvaXp 50 intranasal vaccine in adult volunteers. *Vaccine* **28**, 6076–6085 (2010).
33. El-Kamary, S. S. *et al.* Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. *J. Infect. Dis.* **202**, 1649–1658 (2010).
34. Heinonen, S. *et al.* Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. *Lancet Infect. Dis.* **11**, 23–29 (2011).
35. DeRoeck, D. *et al.* Typhoid vaccination: the Asian experience. *Expert Rev. Vaccines* **7**, 547–560 (2008).
36. Shin, S., Desai, S. N., Sah, B. K. & Clemens, J. D. Oral vaccines against cholera. *Clin. Infect. Dis.* **52**, 1343–1349 (2011).
37. Zakay-Rones, Z. Human influenza vaccines and assessment of immunogenicity. *Expert Rev. Vaccines* **9**, 1423–1439 (2010).
38. Madhi, S. A. *et al.* Effect of human rotavirus vaccine on severe diarrhea in African infants. *N. Engl. J. Med.* **362**, 289–298 (2010).
39. Vesikari, T. *et al.* Safety and efficacy of a pentavalent human–bovine (WC5) reassortant rotavirus vaccine. *N. Engl. J. Med.* **354**, 23–33 (2006). **A classical study on the protective efficacy of a rotavirus vaccine.**
40. Grimwood, K. & Forbes, D. A. Acute and persistent diarrhea. *Pediatr. Clin. North Am.* **56**, 1343–1361 (2009).
41. Jaensson-Gyllenback, E. *et al.* Bile retinoids imprint intestinal CD103<sup>+</sup> dendritic cells with the ability to generate gut-tropic T cells. *Mucosal Immunol.* **4**, 438–447 (2011).
42. Cooper, P. J. *et al.* Impact of early life exposures to geohelminth infections on the development of vaccine immunity, allergic sensitization, and allergic inflammatory diseases in children living in tropical Ecuador: the ECUAVIDA birth cohort study. *BMC Infect. Dis.* **11**, 184 (2011).
43. Holmgren, J. Actions of cholera toxin and the prevention and treatment of cholera. *Nature* **292**, 413–417 (1981).
44. Quiding, M. *et al.* Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon- $\gamma$  production and evokes local immunological memory. *J. Clin. Invest.* **88**, 143–148 (1991). **One of the first convincing studies demonstrating the ability to generate immunological memory through oral vaccination.**
45. Shamsuzzaman, S. *et al.* Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent *V. cholerae* O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. *Vaccine* **27**, 1386–1392 (2009).
46. Svennerholm, A. M. & Holmgren, J. Oral vaccines against cholera and enterotoxigenic *Escherichia coli* diarrhea. *Adv. Exp. Med. Biol.* **371B**, 1623–1628 (1995).
47. Ali, M. *et al.* Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. *Lancet* **366**, 44–49 (2005). **An excellent description of herd immunity and its consequences for vaccine-induced protection.**
48. Wijburg, O. L. *et al.* Innate secretory antibodies protect against natural *Salmonella typhimurium* infection. *J. Exp. Med.* **203**, 21–26 (2006).
49. Czerkinsky, C. & Holmgren, J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. *Curr. Top. Microbiol. Immunol.* **354**, 1–18 (2010).
50. Chadwick, S., Kriegel, C. & Amiji, M. Nanotechnology solutions for mucosal immunization. *Adv. Drug Deliv. Rev.* **62**, 394–407 (2010). **A comprehensive and detailed description of the novel nanotechnologies that may change mucosal vaccine development.**
51. Peek, L. J., Middaugh, C. R. & Berkland, C. Nanotechnology in vaccine delivery. *Adv. Drug Deliv. Rev.* **60**, 915–928 (2008).
52. Brandtzaeg, P. Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. *Am. J. Respir. Crit. Care Med.* **183**, 1595–1604 (2011).
53. Jabbal-Gill, I. Nasal vaccine innovation. *J. Drug Target.* **18**, 771–786 (2010). **A review of current nasal vaccine strategies.**
54. Krejtz, J. H., Fouchier, R. A. & Rimmelzwaan, G. F. Immune responses to influenza virus infection. *Virus Res.* **162**, 19–30 (2011).
55. Bakke, H. *et al.* Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. *Scand. J. Immunol.* **63**, 223–231 (2006).
56. Djupesland, P. G. & Skretting, A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. *J. Aerosol Med. Pulm. Drug Deliv.* **17** Jan 2012 (doi:10.1089/jamp.2011.0924). **This paper reports on the development of nasal vaccine devices.**



57. Mestecky, J., Alexander, R. C., Wei, Q. & Moldoveanu, Z. Methods for evaluation of humoral immune responses in human genital tract secretions. *Am. J. Reprod. Immunol.* **65**, 361–367 (2011).
58. Bomsel, M. *et al.* Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. *Immunity* **34**, 269–280 (2011).
59. Lopalco, L. & Bomsel, M. Protecting the initial site of viral entry: an alternative HIV vaccine target. *Expert Rev. Vaccines* **10**, 1253–1256 (2011). **This article outlines successful approaches to mucosal HIV vaccination.**
60. Marks, E., Helgeby, A., Andersson, J. O., Schon, K. & Lycke, N. Y. Elicitation of CD4<sup>+</sup> T cell immunity in the female genital tract is critically dependent on local mucosal immunization. *Eur. J. Immunol.* **41**, 2642–2653 (2011). **The study shows that CTA1-DD cannot bind to the cells of the central nervous tissues following intranasal administration.**
61. Wegmann, F. Mucosally-targeted HIV-1 vaccines. *Hum. Vaccin.* **7**, 982–985 (2011).
62. Lewis, D. J. *et al.* Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. *PLoS ONE* **6**, e25165 (2011).
63. Czerkinsky, C., Cuburu, N., Kweon, M. N., Anjuere, F. & Holmgren, J. Sublingual vaccination. *Hum. Vaccin.* **7**, 110–114 (2011).
64. Kweon, M. N. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. *Cytokine* **54**, 1–5 (2011). **This article critically reviews various aspects of sublingual vaccination.**
65. Carmichael, J. R., Pal, S., Tifrea, D. & de la Maza, L. M. Induction of protection against vaginal shedding and infertility by a recombinant *Chlamydia* vaccine. *Vaccine* **29**, 5276–5283 (2011).
66. Cho, H. J. *et al.* Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. *Vaccine* **28**, 2598–2606 (2010).
67. Domm, W. *et al.* Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier. *Vaccine* **29**, 7080–7089 (2011).
68. Song, J. H. *et al.* Sublingual vaccination with influenza virus protects mice against lethal viral infection. *Proc. Natl Acad. Sci. USA* **105**, 1644–1649 (2008).
69. Flach, C. F. *et al.* A truncated form of HpaA is a promising antigen for use in a vaccine against *Helicobacter pylori*. *Vaccine* **29**, 1235–1241 (2011).
70. Huo, Z. *et al.* Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. *PLoS ONE* **7**, e33736 (2012).
71. van der Lubben, I. M., Verhoef, J. C., Borchard, G. & Junginger, H. E. Chitosan for mucosal vaccination. *Adv. Drug Deliv. Rev.* **52**, 139–144 (2001).
72. Garg, N. K., Mangal, S., Khambete, H. & Tyagi, R. K. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. *Recent Pat. Drug Deliv. Formul.* **4**, 114–128 (2010).
73. Wassen, L., Schon, K., Holmgren, J., Jertborn, M. & Lycke, N. Local intravaginal vaccination of the female genital tract. *Scand. J. Immunol.* **44**, 408–414 (1996). **This study demonstrates the efficiency of intravaginal vaccination.**
74. Eliasson, D. G. *et al.* A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. *Vaccine* **29**, 3951–3961 (2011). **This study describes in detail the benefits of combined vectors for mucosal vaccination.**
75. Ishii, M. & Kojima, N. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. *Glycoconj. J.* **27**, 115–123 (2010).
76. Schneider-Ohrum, K. & Ross, T. M. Virus-like particles for antigen delivery at mucosal surfaces. *Curr. Top. Microbiol. Immunol.* **354**, 53–73 (2011).
77. Kuolee, R. & Chen, W. M cell-targeted delivery of vaccines and therapeutics. *Expert Opin. Drug Deliv.* **5**, 693–702 (2008).
78. Kelsall, B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. *Mucosal Immunol.* **1**, 460–469 (2008). **An excellent description of DC subsets in the gut immune system.**
79. Azizi, A., Kumar, A., Diaz-Mitoma, F. & Mestecky, J. Enhancing oral vaccine potency by targeting intestinal M cells. *PLoS Pathog.* **6**, e1001147 (2010).
80. Galli, G. *et al.* Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted pre-pandemic vaccine. *Proc. Natl Acad. Sci. USA* **106**, 7962–7967 (2009).
81. Dormitzer, P. R. *et al.* Influenza vaccine immunology. *Immunol. Rev.* **239**, 167–177 (2011).
82. Elson, C. O. & Dertzbaugh, M. T. in *Mucosal Immunology* (eds Mestecky, J. *et al.*) 967–986 (Elsevier Academic Press, 2005).
83. Lambrecht, B. N., Kool, M., Willart, M. A. & Hammad, H. Mechanism of action of clinically approved adjuvants. *Curr. Opin. Immunol.* **21**, 23–29 (2009). **A clear and concise description of current vaccine adjuvants and their mechanisms of action.**
84. Harandi, A. M. & Medagliani, D. Mucosal adjuvants. *Curr. HIV Res.* **8**, 330–335 (2010).
85. Blaas, S. H., Stieber-Gunckel, M., Falk, W., Obermeier, F. & Rogler, G. CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. *Clin. Exp. Immunol.* **155**, 534–540 (2009).
86. Uematsu, S. *et al.* Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. *Nature Immunol.* **9**, 769–776 (2008). **An important study demonstrating the role of TLR5 signalling in gut IgA-mediated immunity.**
87. Boyaka, P. N. *et al.* Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. *J. Immunol.* **166**, 2283–2290 (2001).
88. Christensen, D. *et al.* Liposome-based cationic adjuvant formulations (CAF): past, present, and future. *J. Liposome Res.* **19**, 2–11 (2009).
89. Kool, M. *et al.* Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. *J. Immunol.* **181**, 3755–3759 (2008).
90. Malyala, P. *et al.* The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. *J. Pharm. Sci.* **97**, 1155–1164 (2008).
91. Freytag, L. C., Clements, J. D., Grdic Eliasson, D. & Lycke, N. in *New Generation Vaccines* (ed. Levine, M.M.) 273–283 (Informa, 2010). **This article reviews the role of the bacterial enterotoxins cholera toxin and E. coli heat-labile enterotoxin in mucosal vaccine efficacy.**
92. Liang, S. & Hajishengallis, G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. *Immunol. Invest.* **39**, 449–467 (2010).
93. Spangler, B. D. Structure and function of cholera toxin and the related *Escherichia coli* heat-labile enterotoxin. *Microbiol. Rev.* **56**, 622–647 (1992).
94. Fahlen-Yrild, L. *et al.* CD11c<sup>hi</sup> dendritic cells are essential for activation of CD4<sup>+</sup> T cells and generation of specific antibodies following mucosal immunization. *J. Immunol.* **183**, 5032–5041 (2009).
95. Connell, T. D. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. *Expert Rev. Vaccines* **6**, 821–834 (2007).
96. Snider, D. P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. *Crit. Rev. Immunol.* **15**, 317–348 (1995).
97. Anosova, N. G. *et al.* Cholera toxin, *E. coli* heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. *Mucosal Immunol.* **1**, 59–67 (2008).
98. Fujihashi, K., Koga, T., van Ginkel, F. W., Hagiwara, Y. & McGhee, J. R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. *Vaccine* **20**, 2431–2438 (2002).
99. Glueck, R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. *Vaccine* **20**, S42–S44 (2001).
100. Mutsch, M. *et al.* Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. *N. Engl. J. Med.* **350**, 896–903 (2004). **An informative example of holotoxin-mediated side effects after nasal vaccination.**
101. Levine, M. M. *et al.* Evaluation in humans of attenuated *Vibrio cholerae* El Tor Ogawa strain Texas Star-SR as a live oral vaccine. *Infect. Immun.* **43**, 515–522 (1984).
102. Pizza, M. *et al.* Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. *Vaccine* **19**, 2534–2541 (2001). **A classical review of mucosal vaccine strategies based on holotoxins or derivatives thereof.**
103. Summerton, N. A. *et al.* Toward the development of a stable, freeze-dried formulation of *Helicobacter pylori* killed whole cell vaccine adjuvanted with a novel mutant of *Escherichia coli* heat-labile toxin. *Vaccine* **28**, 1404–1411 (2010).
104. Brereton, C. F. *et al.* *Escherichia coli* heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. *J. Immunol.* **186**, 5896–5906 (2011). **Mechanistic studies of E. coli heat-labile enterotoxin and LTK63 and their role for augmenting T<sub>H</sub>17 cell responses.**
105. Lewis, D. J. *et al.* Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of *Escherichia coli* heat labile toxin. *PLoS ONE* **4**, e6999 (2009).
106. Hagiwara, Y. *et al.* A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. *J. Immunol.* **177**, 3045–3054 (2006).
107. Agren, L. C., Ekman, L., Lowenadler, B. & Lycke, N. Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. *J. Immunol.* **158**, 3936–3946 (1997). **The first description of the CTA1-DD adjuvant.**
108. Lycke, N. & Bemark, M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. *Mucosal Immunol.* **3**, 556–566 (2010).
109. Eriksson, A. M., Schon, K. M. & Lycke, N. Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. *J. Immunol.* **173**, 3310–3319 (2004).
110. Sundling, C. *et al.* CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. *J. Gen. Virol.* **89**, 2954–2964 (2008).
111. Hasselberg, A., Schon, K., Tarkowski, A. & Lycke, N. Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. *Arthritis Rheum.* **60**, 1672–1682 (2009). **The first demonstration that mutated CTA1-DD could work to tolerize CD4<sup>+</sup> T cells in the context of autoimmune conditions.**
112. Hasselberg, A., Ekman, L., Yrild, L. F., Schon, K. & Lycke, N. Y. ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization. *J. Immunol.* **184**, 2776–2784 (2010).
113. Plotkin, S. A. Correlates of protection induced by vaccination. *Clin. Vaccine Immunol.* **17**, 1055–1065 (2010). **A critical review of the correlates of protection in mucosal vaccines.**
114. Alam, M. M. *et al.* Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. *Clin. Vaccine Immunol.* **18**, 844–850 (2011).
115. Di Fabio, S. *et al.* Vaginal immunization of Cynomolgus monkeys with *Streptococcus gordonii* expressing HIV-1 and HPV 16 antigens. *Vaccine* **16**, 485–492 (1998).
116. Rudenko, L. *et al.* Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. *Vaccine* **29**, A40–A44 (2011).
117. Tengvall, S., Lundgren, A., Quiding-Jarbrink, M. & Svennerholm, A. M. BAFF, stimulatory DNA and IL-15 stimulates IgA<sup>+</sup> memory B cells and provides a novel approach for analysis of memory responses to mucosal vaccines. *Vaccine* **28**, 5445–5450 (2010).
118. Lycke, N. & Holmgren, J. Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. *Scand. J. Immunol.* **25**, 407–412 (1987).
119. Lycke, N. & Holmgren, J. Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin. *Infect. Immun.* **57**, 1137–1141 (1989).

120. Bergqvist, P. *et al.* Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses. *Mucosal Immunol.* 11 Jul 2012 (doi:10.1038/mi.2012.56).  
**This first study to provide evidence that antigen-specific gut IgA responses expand in multiple Peyer's patches by re-using already existing germinal centres.**
121. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu. Rev. Immunol.* **22**, 745–763 (2004).
122. McAleer, J. P. & Kolls, J. K. Mechanisms controlling Th17 cytokine expression and host defense. *J. Leukoc. Biol.* **90**, 263–270 (2011).
123. Ohnmacht, C. *et al.* Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity. *Cell. Microbiol.* **13**, 653–659 (2011).
124. Esplugues, E. *et al.* Control of T<sub>H</sub>17 cells occurs in the small intestine. *Nature* **475**, 514–518 (2011).
125. Howie, S. E., Horner, P. J., Horne, A. W. & Entrican, G. Immunity and vaccines against sexually transmitted *Chlamydia trachomatis* infection. *Curr. Opin. Infect. Dis.* **24**, 56–61 (2011).
126. Velin, D. & Michetti, P. Advances in vaccination against *Helicobacter pylori*. *Expert Rev. Gastroenterol. Hepatol.* **4**, 157–166 (2010).  
**This article discusses various aspects of H. pylori vaccine development that may point to more successful approaches.**
127. Woodland, D. L. & Kohlmeier, J. E. Migration, maintenance and recall of memory T cells in peripheral tissues. *Nature Rev. Immunol.* **9**, 153–161 (2009).
128. Shortman, K., Lahoud, M. H. & Caminschi, I. Improving vaccines by targeting antigens to dendritic cells. *Exp. Mol. Med.* **41**, 61–66 (2009).  
**This article describes in detail DC-targeting strategies.**
129. Caminschi, I. *et al.* The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. *Blood* **112**, 3264–3273 (2008).
130. Fang, Y., Larsson, L., Mattsson, J., Lycke, N. & Xiang, Z. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation. *J. Immunol.* **185**, 2935–2941 (2010).
131. Nakaya, H. I. & Pulendran, B. Systems vaccinology: its promise and challenge for HIV vaccine development. *Curr. Opin. HIV AIDS* **7**, 24–31 (2012).
132. Six, A., Bellier, B., Thomas-Vaslin, V. & Klatzmann, D. Systems biology in vaccine design. *Microb. Biotechnol.* **5**, 295–304 (2011).
133. White, O. J. *et al.* A genomics-based approach to assessment of vaccine safety and immunogenicity in children. *Vaccine* **30**, 1865–1874 (2012).
134. Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. *Cell* **124**, 849–863 (2006).
135. Salmi, M. & Jalkanen, S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. *Immunol. Rev.* **206**, 100–113 (2005).
136. Gorfu, G., Rivera-Nieves, J. & Ley, K. Role of  $\beta$ 7 integrins in intestinal lymphocyte homing and retention. *Curr. Mol. Med.* **9**, 836–850 (2009).
137. Mora, J. R. & von Andrian, U. H. Differentiation and homing of IgA-secreting cells. *Mucosal Immunol.* **1**, 96–109 (2008).
138. del Rio, M. L., Bernhardt, G., Rodriguez-Barbosa, J. I. & Forster, R. Development and functional specialization of CD103<sup>+</sup> dendritic cells. *Immunol. Rev.* **234**, 268–281 (2010).
139. Schulz, O. *et al.* Intestinal CD103<sup>+</sup>, but not CX3CR1<sup>+</sup>, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. *J. Exp. Med.* **206**, 3101–3114 (2009).
140. Scott, C. L., Aumeunier, A. M. & Mowat, A. M. Intestinal CD103<sup>+</sup> dendritic cells: master regulators of tolerance? *Trends Immunol.* **32**, 412–419 (2011).  
**A current update on the role of an important DC subset for mucosal immunity and tolerance.**
141. Semmrich, M. *et al.* Directed antigen targeting *in vivo* identifies a role for CD103<sup>+</sup> dendritic cells in both tolerogenic and immunogenic T-cell responses. *Mucosal Immunol.* **5**, 150–160 (2011).  
**This study describes an effective strategy to target antigens to the CD103<sup>+</sup> DC subset.**
142. Cha, H. R. *et al.* Mucosa-associated epithelial chemokine/CCL28 expression in the uterus attracts CCR10<sup>+</sup> IgA plasma cells following mucosal vaccination via estrogen control. *J. Immunol.* **187**, 3044–3052 (2011).
143. Lin, Y., Slight, S. R. & Khader, S. A. Th17 cytokines and vaccine-induced immunity. *Semin. Immunopathol.* **32**, 79–90 (2010).
144. Khader, S. A., Gaffen, S. L. & Kolls, J. K. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. *Mucosal Immunol.* **2**, 403–411 (2009).
145. Belyakov, I. M. & Ahlers, J. D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? *J. Immunol.* **183**, 6883–6892 (2009).
146. Mattsson, J. *et al.* Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. *J. Immunol.* **187**, 3641–3652 (2011).  
**This study demonstrates that adjuvants can bind to and activate follicular DCs.**
147. Bemark, M. *et al.* A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development. *J. Immunol.* **186**, 1399–1410 (2011).
148. Dhere, R. *et al.* A pandemic influenza vaccine in India: from strain to sale within 12 months. *Vaccine* **29**, A16–A21 (2011).
149. Aylward, R. B. Eradicating polio: today's challenges and tomorrow's legacy. *Ann. Trop. Med. Parasitol.* **100**, 401–413 (2006).
150. Sabin, A. B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. *J. Infect. Dis.* **151**, 420–436 (1985).
151. Ferreccio, C., Levine, M. M., Rodriguez, H. & Contreras, R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. *J. Infect. Dis.* **159**, 766–769 (1989).
152. Shafique, M., Wilschut, J. & de Haan, A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. *Vaccine* **30**, 597–606 (2012).
153. Elson, C. O. Cholera toxin and its subunits as potential oral adjuvants. *Curr. Top. Microbiol. Immunol.* **146**, 29–33 (1989).
154. Agren, L. C., Ekman, L., Lowenader, B., Nedrud, J. G. & Lycke, N. Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. *J. Immunol.* **162**, 2432–2440 (1999).
155. Muhammad, A., Champeimont, J., Mayr, U. B., Lubitz, W. & Kudela, P. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. *Expert Rev. Vaccines* **11**, 97–116 (2012).
156. Thompson, A. L. *et al.* Maximal adjuvant activity of nasally delivered IL-1 $\alpha$  requires adjuvant-responsive CD11c<sup>+</sup> cells and does not correlate with adjuvant-induced *in vivo* cytokine production. *J. Immunol.* **188**, 2834–2846 (2012).
157. Winstone, N. *et al.* Enhanced control of pathogenic simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime–viral vector boost vaccine regimen. *J. Virol.* **85**, 9578–9587 (2011).

#### Acknowledgements

I would like to thank all past and present members of my research group for their devotion and hard work. Special thanks to M. Bemark for collaborative work on gut IgA B cell immunity and to B. Löwenader, co-inventor of the CTA1-DD adjuvant. Lastly, I would like to thank my mentor and friend W. Strober for always giving generous support and engaging in helpful discussions.

#### Competing interests statement

The authors declare no competing financial interests.